Liver function dynamics in advanced hepatocellular carcinoma receiving immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization
TACE combined with ICIs plus anti-VEGF antibodies/TKIs as first-line treatment generally did not adversely affect liver function. Liver function deterioration was associated with an increased risk of mortality.
Authors
- M L Wang
- C Liu
- Shuai Zhang (ORCID: https://orcid.org/0000-0002-0648-921X)
- Ze Wang (ORCID: https://orcid.org/0000-0002-8339-5567)
- Jian Shen (ORCID: https://orcid.org/0000-0003-1877-586X)
- Hao-Dong Wu
- X. P. Xu
- Xiaoli Zhu
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251347363
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00